Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 3, 28 April 2023
Open
Access | Article
HER 2 Targeted Therapy and Its Potential Risk of Drug Resistance
* Author to whom correspondence should be addressed.
Abstract
HER2, human epidermal receptor 2(c-erbB-2 gene), is a hot targeted point in various cancer’s targeted therapy. Breast cancer including HER2 positive or negative. HER2 is an oncogenic receptor tyrosine kinase. HER2 gene amplification occurs in some of breast cancers (BCS), resulting in overexpression of the HER2 protein. Compared to the trastuzumab or pertuzumab, the performance of trastuzumab deruxtecan is excellent. Drug resistance is known to be the main cause of failure of tumor chemotherapy. Tumor drug resistance involves various mechanisms, such as those involving decreased intracellular drug concentration, changes of drug target molecules, metabolic detoxification, and imbalance of DNA damage repair function. HER2-positive breast cancer becomes resistant to trastuzumab, thereby blocking effective binding and developing resistance. The significance of this review is to understand the mechanism of drug resistance from molecular and chemotherapy perspectives by studying the structure and overexpression of HER2 protein as predictors, so as to grasp the progress of current targeted drug therapy. Our review starting from HER2 and its targeted therapy gets to the deep insight into the antibody drug conjugates and explores the possible proteins which may become the potential targeted points in future research.
Keywords
HER2, targeted therapy, antibody-drug conjugates (ADC)
References
1. MM Moasser. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007 Oct 4;26(45):6469-87.
2. V Hart, H Gautrey, J Kirby, A Tyson-Capper. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes. Oncotarget. 2020 Nov 17;11(46):4338-4357.
3. A Appert-Collin, P Hubert, G Crémel, A Bennasroune. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015 Nov 24; 6:283.
4. Q Lv, Z Meng, Y Yu, F Jiang, D Guan, C Liang, J Zhou, A Lu, G. Zhang Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci. 2016 Dec 14;17(12):2095.
5. Z. Fu, S. Li, S. Han, C. Shi, &, Y. Zhang. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1), 93. (2022)
6. S. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N. T. Ueno, A. Prat, Y. S. Chae, K. S. Lee, N. Niikura, Y. H. Park, B. Xu, X. Wang, M. Gil-Gil, W. Li, J. Y. Pierga, S. A. Im, H. Moore … DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387(1), 9–20. (2022)
7. C. H. Chau, P. S. Steeg, & W. D. Figg, Antibody-drug conjugates for cancer. Lancet (London, England), 394(10200), 793–804. (2019)
8. M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, & J. Baselga. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute, 99(8), 628–638. (2007)
9. Rius Ruiz Irene, Vicario Rocio, Morancho Beatriz et al. p95HER2-T cell bispecific antibody for breast cancer treatment.[J] .Sci Transl Med, 2018.
10. C. A. Dreyer, K. Vander Vorst, S. Free, A Rowson-Hodel, & K. L. Carraway.The role of membrane mucin MUC4 in breast cancer metastasis. Endocrine-Related Cancer, 29(1), R17–R32. (2022)
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
- ISBN (Print)
- 978-1-915371-25-6
- ISBN (Online)
- 978-1-915371-26-3
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/3/20220210
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited